Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
127.75
-1.59 (-1.23%)
At close: Aug 7, 2025, 4:00 PM
128.01
+0.26 (0.20%)
After-hours: Aug 7, 2025, 7:53 PM EDT
Biogen Revenue
Biogen had revenue of $2.65B in the quarter ending June 30, 2025, with 7.33% growth. This brings the company's revenue in the last twelve months to $10.00B, up 3.36% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$10.00B
Revenue Growth
+3.36%
P/S Ratio
1.87
Revenue / Employee
$1,314,530
Employees
7,605
Market Cap
18.73B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BIIB News
- 5 days ago - Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio - Seeking Alpha
- 7 days ago - Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Biogen raises annual profit forecast on strong demand for rare disease drugs - Reuters
- 8 days ago - Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 - GlobeNewsWire
- 8 days ago - Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds - Reuters
- 13 days ago - ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression - GlobeNewsWire
- 17 days ago - Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025 - GlobeNewsWire
- 17 days ago - Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing - Benzinga